BURLINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-founder and Chief Executive Officer of the Company, will present at two upcoming investor conferences.
Details of the presentations can be found below.
Morgan Stanley Global Healthcare Conference
Format: Fireside Chat
Date: 09/06/2024
Time: 10:45 AM ET
H.C. Wainwright 26th Annual Global Investment Conference
Format: Company Presentation
Date: 09/09/2024
Time: 2:00 PM ET
Webcast replays will be accessible following the live sessions on the Events page of the Investors section on the Company’s website at https://ir.fractyl.com/.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com or https://twitter.com/FractylHealth.
Contacts
Corporate Contact
Lisa Davidson, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it., 781.902.8800
Media Contact
Jessica Cotrone, Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it., 978.760.5622
Investor Contact
Stephen Jasper, Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it., 619.949.3681
| Last Trade: | US$2.49 |
| Daily Change: | 0.12 5.06 |
| Daily Volume: | 167,205 |
| Market Cap: | US$119.350M |
August 14, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
